OBJECTIVE: We sought to elucidate the risks for access site-related complications (ASCs) after percutaneous lower extremity revascularization and to evaluate the benefit of routine ultrasound-guided access (RUS) in decreasing ASCs. METHODS: We reviewed all consecutive percutaneous revascularizations (percutaneous transluminal angioplasty or stent) performed for lower extremity atherosclerosis at our institution from 2002 to 2012. RUS began in September 2007. Primary outcome was any ASC (bleeding, groin or retroperitoneal hematoma, vessel rupture, or thrombosis). Multivariable logistic regression was used to determine predictors of ASC. RESULTS: A total of 1371 punctures were performed on 877 patients (43% women; median age, 69 [interquartile range, 60-78] years) for claudication (29%), critical limb ischemia (59%), or bypass graft stenosis (12%) with 4F to 8F sheaths. There were 72 ASCs (5%): 52 instances of bleeding or groin hematoma, nine pseudoaneurysms, eight retroperitoneal hematomas, two artery lacerations, and one thrombosis. ASCs were less frequent when RUS was used (4% vs 7%; P = .02). Multivariable predictors of ASC were age >75 years (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.1-3.7; P = .03), congestive heart failure (OR, 1.9; 95% CI, 1.1-1.3; P = .02), preoperative warfarin use (OR, 2.0; 95% CI, 1.1-3.5; P = .02), and RUS (OR, 0.4; 95% CI, 0.2-0.7; P < .01). Vascular closure devices (VCDs) were not associated with lower rates of ASCs (OR, 1.1; 95% CI, 0.6-1.9; P = .79). RUS lowered ASCs in those >75 years (5% vs 12%; P < .01) but not in those taking warfarin preoperatively (10% vs 13%; P = .47). RUS did not decrease VCD failure (6% vs 4%; P = .79). CONCLUSIONS: We were able to decrease the rate of ASCs during lower extremity revascularization with the implementation of RUS. VCDs did not affect ASCs. Particular care should be taken with patients >75 years old, those with congestive heart failure, and those taking warfarin.
OBJECTIVE: We sought to elucidate the risks for access site-related complications (ASCs) after percutaneous lower extremity revascularization and to evaluate the benefit of routine ultrasound-guided access (RUS) in decreasing ASCs. METHODS: We reviewed all consecutive percutaneous revascularizations (percutaneous transluminal angioplasty or stent) performed for lower extremity atherosclerosis at our institution from 2002 to 2012. RUS began in September 2007. Primary outcome was any ASC (bleeding, groin or retroperitoneal hematoma, vessel rupture, or thrombosis). Multivariable logistic regression was used to determine predictors of ASC. RESULTS: A total of 1371 punctures were performed on 877 patients (43% women; median age, 69 [interquartile range, 60-78] years) for claudication (29%), critical limb ischemia (59%), or bypass graft stenosis (12%) with 4F to 8F sheaths. There were 72 ASCs (5%): 52 instances of bleeding or groin hematoma, nine pseudoaneurysms, eight retroperitoneal hematomas, two artery lacerations, and one thrombosis. ASCs were less frequent when RUS was used (4% vs 7%; P = .02). Multivariable predictors of ASC were age >75 years (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.1-3.7; P = .03), congestive heart failure (OR, 1.9; 95% CI, 1.1-1.3; P = .02), preoperative warfarin use (OR, 2.0; 95% CI, 1.1-3.5; P = .02), and RUS (OR, 0.4; 95% CI, 0.2-0.7; P < .01). Vascular closure devices (VCDs) were not associated with lower rates of ASCs (OR, 1.1; 95% CI, 0.6-1.9; P = .79). RUS lowered ASCs in those >75 years (5% vs 12%; P < .01) but not in those taking warfarin preoperatively (10% vs 13%; P = .47). RUS did not decrease VCD failure (6% vs 4%; P = .79). CONCLUSIONS: We were able to decrease the rate of ASCs during lower extremity revascularization with the implementation of RUS. VCDs did not affect ASCs. Particular care should be taken with patients >75 years old, those with congestive heart failure, and those taking warfarin.
Authors: Eugenia Nikolsky; Roxana Mehran; Amir Halkin; Eve D Aymong; Gary S Mintz; Zoran Lasic; Manuela Negoita; Martin Fahy; Shoshana Krieger; Issam Moussa; Jeffrey W Moses; Gregg W Stone; Martin B Leon; Stuart J Pocock; George Dangas Journal: J Am Coll Cardiol Date: 2004-09-15 Impact factor: 24.094
Authors: Sumeet Subherwal; Eric D Peterson; David Dai; Laine Thomas; John C Messenger; Ying Xian; Ralph G Brindis; Dmitriy N Feldman; Shaun Senter; Lloyd W Klein; Steven P Marso; Matthew T Roe; Sunil V Rao Journal: J Am Coll Cardiol Date: 2012-05-22 Impact factor: 24.094
Authors: Vahid Etezadi; Barry T Katzen; Amer Naiem; Amardeep Johar; Scott Wong; Joseph Fuller; James F Benenati Journal: J Vasc Interv Radiol Date: 2010-12-30 Impact factor: 3.464
Authors: Venkatesan D Vidi; Michael E Matheny; Usha S Govindarajulu; Sharon-Lise T Normand; Susan L Robbins; Vikram V Agarwal; Sripal Bangalore; Frederic S Resnic Journal: JACC Cardiovasc Interv Date: 2012-08 Impact factor: 11.195
Authors: Winthrop D Piper; David J Malenka; Thomas J Ryan; Samuel J Shubrooks; Gerald T O'Connor; John F Robb; Karen L Farrell; Mary S Corliss; Michael J Hearne; Mirle A Kellett; Matthew W Watkins; William A Bradley; Bruce D Hettleman; Theodore M Silver; Paul D McGrath; John R O'Mears; David E Wennberg Journal: Am Heart J Date: 2003-06 Impact factor: 4.749
Authors: Joel L Ramirez; Devin S Zarkowsky; Thomas A Sorrentino; Caitlin W Hicks; Shant M Vartanian; Warren J Gasper; Michael S Conte; James C Iannuzzi Journal: J Vasc Surg Date: 2020-03-09 Impact factor: 4.268
Authors: Dominique B Buck; Eleonora G Karthaus; Peter A Soden; Klaas H J Ultee; Joost A van Herwaarden; Frans L Moll; Marc L Schermerhorn Journal: J Vasc Surg Date: 2015-03-28 Impact factor: 4.268
Authors: Patric Liang; Thomas F X O'Donnell; Nicholas J Swerdlow; Chun Li; Andy Lee; Mark C Wyers; Allen D Hamdan; Marc L Schermerhorn Journal: J Vasc Surg Date: 2019-03-07 Impact factor: 4.268
Authors: Peter A Soden; Sara L Zettervall; Thomas Curran; Ageliki G Vouyouka; Philip P Goodney; Joseph L Mills; John W Hallett; Marc L Schermerhorn Journal: J Vasc Surg Date: 2016-09-28 Impact factor: 4.268
Authors: Craig M Walker; Jihad Mustapha; Thomas Zeller; Andrej Schmidt; Miguel Montero-Baker; Aravinda Nanjundappa; Marco Manzi; Luis Mariano Palena; Nelson Bernardo; Yazan Khatib; Robert Beasley; Luis Leon; Fadi A Saab; Adam R Shields; George L Adams Journal: J Endovasc Ther Date: 2016-08-24 Impact factor: 3.487